Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner (Q38333159)

2 September 2017

Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner (English)

1 reference

2 September 2017

0 references

0 references

Cryptococcus neoforman

1 reference

3

Arthur M Krieg

1 reference

2 September 2017

Lorna Edwards

1

1 reference

2 September 2017

Andrew E Williams

2

1 reference

2 September 2017

Aaron J Rae

4

1 reference

2 September 2017

Robert J Snelgrove

5

1 reference

2 September 2017

Tracy Hussell

6

1 reference

2 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

European Journal of Immunology

2 September 2017

1 reference

2 September 2017

35

1 reference

2 September 2017

1

1 reference

2 September 2017

273-281

1 reference

Recent advances in the epidemiology, prevention, diagnosis, and treatment of fungal pneumonia

2 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

IL-12-activated NK cells reduce lung eosinophilia to the attachment protein of respiratory syncytial virus but do not enhance the severity of illness in CD8 T cell-immunodeficient conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

The contribution of the Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

Inhibition of IL-10 receptor function in alveolar macrophages by Toll-like receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

Pathogenicity of Cryptococcus neoformans: virulence factors and immunological mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Innate and adaptive determinants of host susceptibility to medically important fungi

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Intrapulmonary growth and dissemination of an avirulent strain of Cryptococcus neoformans in mice depleted of CD4+ or CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Differences in components at delayed-type hypersensitivity reaction sites in mice immunized with either a protective or a nonprotective immunogen of Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Characterization of cellular infiltrates and cytokine production during the expression phase of the anticryptococcal delayed-type hypersensitivity response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Induced humoral immunity and vaccination against major human fungal pathogens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG oligodeoxynucleotides enhance host defense during murine tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Toll-like receptors: function and roles in lung disease

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Macrophage priming by interferon gamma: a selective process with potentially harmful effects

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG oligodeoxynucleotides: a novel therapeutic approach for atopic disorders.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

The role of CpG motifs in innate immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Therapeutics targeting the innate immune system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Involvement of CD14, toll-like receptors 2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Toll-like receptors and innate antifungal responses

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

IL-18 modulates chronic fungal asthma in a murine model; putative involvement of Toll-like receptor-2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG DNA-mediated immune response in pulmonary endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

An immunostimulatory oligodeoxynucleotide containing a cytidine-guanosine motif protects senescence-accelerated mice from lethal influenza virus by augmenting the T helper type 1 response

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

MyD88 primes macrophages for full-scale activation by interferon-gamma yet mediates few responses to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200425640

7 January 2021

Identifiers

DOI

10.1002/EJI.200425640

1 reference

2 September 2017

1 reference